Results released today from the Pre-Exposure Prophylaxis Initiative (iPrEx) study confirmed that daily oral use of a combination antiretroviral (ARV), Truvada, reduced the risk of HIV infection by 44 percent among men who have sex with men. This historic iPrEx trial provides the first proof of concept that oral PrEP of an ARV can prevent HIV transmission.

The U.S. Agency for International Development (USAID) congratulates the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, Gladstone Institute of Virology and Immunology-UCSF, and most importantly, the 2,499 pioneering participants who volunteered for this important clinical trial on the promising results from iPrEx.  Global iPrEx is the first large efficacy study to evaluate the use of pre-exposure prophylaxis (PrEP) in men who have sex with men in Africa, Asia, and North and South America.

These promising results also encourage other research partners to continue working on more PrEP and microbicide options which may lead to new tools for HIV prevention.  The AIDS pandemic calls for a dynamic variety of HIV prevention methods to ensure those at risk have choices to use the one that best suits the needs of their lifestyle.

According to new UNAIDS estimates, women worldwide account for more than half of all HIV infections, and in sub-Saharan Africa continue to bear the brunt of the AIDS epidemic, USAID will continue critical research and development work in PrEP for women at high risk.  The FemPrEP clinical trial—led by FHI with support from USAID—is designed to test the safety and effectiveness of a daily dose of Truvada for HIV prevention.  Close to 4,000 HIV-negative women who are at higher risk of HIV are being enrolled in five sites in four countries: Kenya, South Africa, Tanzania, and Zimbabwe; results are expected 2012.

Based on the positive results from the CAPRISA 004 trial which were released in July, USAID will continue to support the regulatory approval of 1% tenofovir gel after further confirmation of its effectiveness.  USAID is committed to ensuring the launch of a new generation of products designed expressly for women and capable of preventing the transmission of HIV.

Finding a woman-controlled method of prevention is critical in the fight against HIV/AIDS.  In line with President Obama’s Global Health Initiative, USAID is committed to focusing on the needs of women and girls in its health programming worldwide.

USAID continues to build on a solid foundation of robust science and new technologies, enabling innovation to redefine and strengthen U.S. development assistance globally.